Deutsche Bank AG Purchases New Holdings in Anika Therapeutics Inc. $ANIK

Deutsche Bank AG purchased a new stake in Anika Therapeutics Inc. (NASDAQ:ANIK) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 353,552 shares of the biotechnology company’s stock, valued at approximately $5,172,000.

Several other institutional investors have also recently made changes to their positions in the stock. Opaleye Management Inc. raised its stake in shares of Anika Therapeutics by 49.1% during the 2nd quarter. Opaleye Management Inc. now owns 588,797 shares of the biotechnology company’s stock worth $6,229,000 after purchasing an additional 193,797 shares in the last quarter. State Street Corp grew its stake in shares of Anika Therapeutics by 4.1% in the fourth quarter. State Street Corp now owns 336,543 shares of the biotechnology company’s stock valued at $3,234,000 after buying an additional 13,165 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Anika Therapeutics by 78.1% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 195,585 shares of the biotechnology company’s stock worth $1,880,000 after buying an additional 85,771 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Anika Therapeutics by 153.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 164,926 shares of the biotechnology company’s stock worth $1,585,000 after buying an additional 99,951 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in Anika Therapeutics by 171.0% during the fourth quarter. Jane Street Group LLC now owns 134,768 shares of the biotechnology company’s stock worth $1,295,000 after buying an additional 85,029 shares during the last quarter. Institutional investors and hedge funds own 91.53% of the company’s stock.

Analysts Set New Price Targets

ANIK has been the subject of a number of analyst reports. Barrington Research set a $21.00 price objective on shares of Anika Therapeutics in a research report on Thursday, July 30th. Zacks Research raised shares of Anika Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 5th. Wall Street Zen upgraded shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anika Therapeutics in a research report on Wednesday, June 24th. Finally, B. Riley Financial boosted their price objective on Anika Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Anika Therapeutics Trading Down 2.0%

ANIK opened at $21.34 on Tuesday. Anika Therapeutics Inc. has a 1-year low of $8.37 and a 1-year high of $22.88. The company has a market cap of $285.59 million, a P/E ratio of -79.03, a PEG ratio of 15.56 and a beta of 0.20. The company’s 50 day moving average is $17.19 and its 200-day moving average is $15.09.

Anika Therapeutics (NASDAQ:ANIK) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.39. The firm had revenue of $32.61 million for the quarter, compared to analysts’ expectations of $29.21 million. Anika Therapeutics had a negative net margin of 3.14% and a positive return on equity of 0.20%. On average, equities analysts forecast that Anika Therapeutics Inc. will post 0.14 EPS for the current year.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.